A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Reynolds, Steven J ^a,b   Kityo, Cissy ^c   Hallahan, Claire W ^a   Kabuye, Geoffrey ^c   Atwiine, Diana ^c   Mbamanya, Frank ^c   Ssali, Francis ^c   Dewar, Robin ^d   Daucher, Marybeth ^a   Davey Jr , Richard T ^a   Mugyenyi, Peter ^c   Fauci, Anthony S ^a   Quinn, Thomas C ^a,b   Dybul, Mark R ^e,f  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^d NATIONAL CANCER INSTITUTE   (United States)

^e GEORGETOWN UNIVERSITY LAW CENTER   (United States)

^f George W Bush Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; STAVUDINE; ZIDOVUDINE; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG INTERMITTENT THERAPY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PERIPHERAL NEUROPATHY; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SIDE EFFECT; TREATMENT DURATION; UGANDA; VIRUS LOAD; BLOOD; DRUG ADMINISTRATION; DRUG EFFECT; METHODOLOGY; MIDDLE AGED; MORTALITY; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; RNA, VIRAL; TREATMENT FAILURE; TREATMENT OUTCOME; UGANDA; VIRAL LOAD;

EID: 77956405792     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010307     Document Type: Article

References (32)

1. Bussmann H, Wester CW, Ndwapi N, Grundmann N, Gaolathe T, et al. (2008) Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS 22: 2303-2311.
2. Jahn A, Floyd S, Crampin AC, Mwaungulu F, Mvula H, et al. (2008) Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet 371: 1603-1611.
3. Lowrance DW, Makombe S, Harries AD, Shiraishi RW, Hochgesang M, et al. (2008) A public health approach to rapid scale-up of antiretroviral treatment in Malawi during 2004-2006. J Acquir Immune Defic Syndr 49: 287-293.
4. McComsey GA, Libutti DE, O'Riordan M, Shelton JM, Storer N, et al. (2008) Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy and not to HIV infection. Antivir Ther 13: 715-722.
5. Nelson M, Azwa A, Sokwala A, Harania RS, Stebbing J (2008) Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy. AIDS 22: 1374-1376.
6. Parruti G, Manzoli L, Toro PM, D'Amico G, Rotolo S, et al. (2006) Long-term adherence to first-line highly active antiretroviral therapy in a hospital-based cohort: predictors and impact on virologic response and relapse. AIDS Patient Care STDS 20: 48-56.
7. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 1-161. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
8. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG (2009) Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373: 48-57.
9. Ananworanich J, Gayet-Ageron A, Le BM, Prasithsirikul W, Chetchotisakd P, et al. (2006) CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 368: 459-465.
10. Dybul M, Nies-Kraske E, Daucher M, Hertogs K, Hallahan CW, et al. (2003) Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters. J Infect Dis 188: 388-396.
11. Papasavvas E, Kostman JR, Mounzer K, Grant RM, Gross R, et al. (2004) Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. PLoS Med 1: e64.
12. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, et al. (2006) CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355: 2283-2296.
13. El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, et al. (2008) Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med 149: 289-299.
14. Danel C, Moh R, Minga A, Anzian A, Ba-Gomis O, et al. (2006) CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 367: 1981-1989.
15. Dybul M, Nies-Kraske E, Dewar R, Maldarelli F, Hallahan CW, et al. (2004) A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection. J Infect Dis 189: 1974-1982.
16. Frost SD, Martinez-Picado J, Ruiz L, Clotet B, Brown AJ (2002) Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infection. J Virol 76: 968-979.
17. Farrington CP, Manning G (1990) Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med 9: 1447-1454.
18. [Anonymous] (2007) StatXact 8 Statistical Software for Exact Nonparametric Inference. 433-435.
19. Agresti A, Min Y (2001) On small-sample confidence intervals for parameters in discrete distributions. Biometrics 57: 963-971.
20. Fay MP (2007) R: A language and environment for statistical computing; rateratio.test: Exact rate ratio test. R package version 1.0.
21. Reynolds SJ, Kityo C, Mbamanya F, Dewar R, Ssali F, et al. (2009) Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda. Antivir Ther 14: 293-297.
22. Cohen CJ, Colson AE, Sheble-Hall AG, McLaughlin KA, Morse GD (2007) Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study. HIV Clin Trials 8: 19-23.
23. Parienti JJ, Das-Douglas M, Massari V, Guzman D, Deeks SG, et al. (2008) Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS ONE 3: e2783.
24. Cohen C, Colson A, Pierone G, DeJesus E, Kinder F, et al. (2008) The FOTO study: 24-week results support the safety of a 2-day break on efavirenz-based antiretroviral therapy. Journal of the International AIDS Society 11 (Suppl 1).
25. Ananworanich J, Nuesch R, Le BM, Chetchotisakd P, Vibhagool A, et al. (2003) Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS 17: F33-F37.
26. Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, et al. (2008) Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS 22: 2279-2289.
27. Levine AJ, Hinkin CH, Marion S, Keuning A, Castellon SA, et al. (2006) Adherence to antiretroviral medications in HIV: differences in data collected via self-report and electronic monitoring. Health Psychol 25: 329-335.
28. McComsey GA, Lo RV, III, O'Riordan M, Walker UA, Lebrecht D, et al. (2008) Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study. Clin Infect Dis 46: 1290-1296.
29. Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD (2008) Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 22: 1971-1977.
30. Moore DM, Mermin J, Awor A, Yip B, Hogg RS, et al. (2006) Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. J Acquir Immune Defic Syndr 43: 436-439.
31. Reynolds SJ, Nakigozi G, Newell K, Ndyanabo A, Galiwongo R, et al. (2009) Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS.
32. World Health Organization (2006) ANTIRETROVIRAL THERAPY FOR HIV INFECTION IN ADULTS AND ADOLESCENTS IN RESOURCE-LIMITED SETTINGS: TOWARDS UNIVERSAL ACCESS Recommendations for a public health approach.